TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06734234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4771261
Description: GSK4771261 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK4771261
Description: Placebo matching GSK4771261 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK4771261
Description: Placebo matching GSK4771261 will be administered.
Study: NCT06749353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: We will use a virtual reality glasses with the 'Lending Moments' program, where patients can experience a sunset on a paradise beach while listening to a soothing voice that guides them through the experience with relaxation and meditation techniques. During this time, we will proceed with the surgical intervention.
Study: NCT06751225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One week replacement soft contact lenses
Description: One week replacement soft contact lenses
Study: NCT06755411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OHFCP2
Description: The proposed intervention consists of a two-phase approach for implementing guidelines and evidence-based recommendations: educating healthcare professionals and enhancing clinical activity.
Study: NCT06760273

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: Observational study, no additional intervention

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: Observational study, no additional intervention
Study: NCT06762639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Sleep Prehabilitation (PSP)
Description: Sleep prehabilitation will consist of usual care prehabilitation (exercise, nutritional support, psychosocial support, education, smoking cessation support, and/or medical care) with the addition of sleep support. This support will consist of:~* Brief behavioural treatment for insomnia~* Sleep hygiene~* Behaviour change support (e.g., goal-setting, use of a wearable tracker to modify behaviour)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Prehabilitation
Description: Exercise, nutritional support, psychosocial support, education, smoking cessation support, and/or medical care delivered by regulated health professionals included Kinesiologists, Dietitians, Clinical Psychologists, etc.
Study: NCT06765291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QuitVaping
Description: QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: This is Quitting (TIQ)
Description: A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: This is Quitting (TIQ)
Description: A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
Study: NCT06766916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisugabalin
Description: Days 1-14: Crisugabalin 40 mg/day, 20 mg twice daily, orally. Days 15-21: Increase dose to 80 mg/day, 40 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 120 mg/day, 60 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Days 1-7: Pregabalin 150 mg/day, 75 mg twice daily, orally. Days 8-14: Increase dose to 300 mg/day, 150 mg twice daily. Days 15-21: Increase dose to 450 mg/day, 225 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 600 mg/day, 300 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.
Study: NCT06767228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reformer Pilates
Description: This intervention involves a structured reformer pilates program designed to enhance core endurance, posture, and body awareness. The program includes exercises such as Footwork Series, Pelvic Lift, Arm Circles, Leg Circles, Frog Series, Long Box Series, Short Box Series, Elephant, Knee Stretch Series, Stomach Massage, and Side Stretch. The program emphasizes progressive resistance, controlled movements, and professional supervision to ensure safety and effectiveness. Sessions are conducted twice weekly for six weeks.
Study: NCT06766643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic radiosurgery for liver lesions: with a total dose of 40\~50Gy/3\~5fraction;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation therapy
Description: Radiofrequency ablation therapy:1 complete radiofrequency ablation of liver lesions for liver lesions
Study: NCT06765603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.025%
Description: Atropine 0.025%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 0.025%
Description: Atropine 0.025%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multizonal contact lens
Description: Multizonal CL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multizonal contact lens
Description: Multizonal CL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision Contact lens
Description: Single vision contact lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single vision Contact lens
Description: Single vision contact lens
Study: NCT06765668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CREXONT ER
Description: CREXONT ER capsule.
Study: NCT06765070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXPLORER
Description: Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.
Study: NCT06764875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilvegostomig
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Q3W, intravenous infusion
Study: NCT04278651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: 510mg infusion x 2 doses 3-8 days apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: 325mg oral twice daily
Study: NCT05588973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDISKIN cream
Description: MEDISKIN cream with collagen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Panthenol cream
Description: Panthenol cream
Study: NCT06764875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: BID, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: BID, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: BID, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Q3W, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Q3W, intravenous infusion
Study: NCT06765837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biolase laser
Description: after secondary cleft lip surgery to improve wound healing and prevent scar formation laser was used with group I and Gel was applied to Group II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blue m gel
Description: active oxygen releasing gel was used after the secondary cleft lip repair surgery
Study: NCT06766994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: Preoperatively, patients will be injected with 200 μg morphine intrathecally with a 27G pencil point spinal needle at the L4-L5 or L3-L4 intervertebral space in a sitting position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Preoperatively, patients will be placed in the prone position before the operation and an ESPB block will be applied bilaterally at the T9 vertebra level with the help of USG. 0.25% bupivacaine 20 ml will be used bilaterally as the blocking fluid.
Study: NCT06765057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Winclove's Ecologic® Barrier Probiotics
Description: The investigational product is a multispecies probiotic formulation consisting of 9 selected probiotic strains: the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Winclove's Ecologic® Barrier Probiotics Placebo
Description: The placebo is composed of the carrier of the probiotic product that are identical in physical appearance, it includes maize starch and maltodextrins but contains no bacteria.
Study: NCT06764563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Medical Nutrition Therapy (counselling)
Description: The participants in the intervention group will receive dietary guidance on the Mediterranean diet during 9 sessions over six months. The sessions which will be held in groups of ten individuals. In-person group sessions will be held three times: at the first meeting, after three months, and after six months. During the remaining six sessions, 6 online video sessions (by the institutional telemedicine program) will be delivered and include 60 minutes of nutritional educational sessions with a registered dietitian once a month
Study: NCT06762561

Intervention type: PROCEDURE
Intervention: Prophylactic retromuscular mesh reinforcement
Description: Prophylactic retromuscular mesh placement involves reinforcing the abdominal wall during closure after open abdominal aortic aneurysm (AAA) repair to prevent incisional hernias. This technique creates a retro-muscular space by carefully dissecting the rectus abdominis muscles from the posterior rectus sheath. A self-gripping polyester mesh or composite mesh is placed in this space, extending 4 cm beyond the midline on each side, ensuring tension-free coverage. The mesh is secured at key points, and the rectus sheaths are closed with continuous sutures. This approach leverages the anatomical integrity of the abdominal wall to reduce hernia risk without increasing postoperative complications.
Study: NCT06766292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary intervention
Description: In the study group: 2.0 mm screws were fixed to the lateral wall of the sinus above the superior osteotomy and placed buccopalatally where the schneiderian membrane was elevated and maintained. this technique will suspends the membrane in position to allow the blood clot to organized and formation of bone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open sinus lifting with xenograft only
Description: ll Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
Study: NCT06766188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Video training for Teachers based on Reading for all
Description: Reading intervention over a year for students with intellectual disabilities who use AAC. There will be 80 participating students and their teachers. It is two arms in the intervention, with approximately 40 in video training for teachers and in person mentoring for teachers. The teachers are randomized into these two groups, but they will carry out the same intervention.~The students in both groups will work explicitly and systematically with the reading material Reading for all, which is based on the research of, among others, Janice Light and David McNaughton, and their reading program Accessible Literacy Learning (ALL).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Video training for Teachers based on Reading for all
Description: Reading intervention over a year for students with intellectual disabilities who use AAC. There will be 80 participating students and their teachers. It is two arms in the intervention, with approximately 40 in video training for teachers and in person mentoring for teachers. The teachers are randomized into these two groups, but they will carry out the same intervention.~The students in both groups will work explicitly and systematically with the reading material Reading for all, which is based on the research of, among others, Janice Light and David McNaughton, and their reading program Accessible Literacy Learning (ALL).
Study: NCT06768164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Billroth 2 (B2)
Description: B2 technique requires a single anastomosis (gastro-jejunostomy) after distal gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-En-Y (REY)
Description: REY technique requires 2 anastomoses (gastro-jejunostomy and entero-enterostomy) after distal gastrectomy
Study: NCT06769308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedation titration according to qEEG
Description: Sedation will be titrated according to the EEG derived indexes (qCON/qNOX)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation titration according to standard of care
Description: Sedation will be provided according to the standard of care of the unit (clinical scales)
Study: NCT06769282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention (SPARE) plus Treatment as Usual
Description: 5 components: (1) Social skills training, including selecting healthy friends and partners, (2) Problem solving with emphasis on positive outcomes of nonaggressive solutions, (3) Awareness of domineering behavior in self and conflict resolution skills, (4) emotion Regulation, and (5) psycho-education on ACEs and trauma. Each session will include 30 minutes of didactic instruction on the component with developmentally engaging activities to illustrate concepts and an individually tailored 15-minute narrative and mindfulness activity, which may address a traumatic memory depending on youth need and receptivity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment As Usual consists of individual, family, occupational, and art therapy, social skills and emotion regulation groups, and therapeutic milieu. All staff and clinicians are trained in the Incredible Years Parenting Program, which aims reduce behavioral problems, enhance children's social and emotional competence, and improve child-parent interactions. Children also receive individualized treatment tailored for their needs (e.g., sleep interventions). Behavioral health needs staff (BHS) facilitate children's skill acquisition and generalization, implement individualized behavior contingency programs, and assist caregivers with parenting strategies via daily check-ins
Study: NCT06767644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no music
Description: Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
Study: NCT06767540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo subcutaneous injection Q2W until week 46.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo subcutaneous injection Q3W until week 45.
Study: NCT06765304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical education intervention group
Description: The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preconceptional Period Healthy Life Behaviours Classical Education Intervention Group
Description: The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
Study: NCT06768840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral mini pulse
Description: pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrow Band UVB Treatment
Description: narrowband ultraviolet rays B phototherapy two sessions per week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrow Band UVB Treatment
Description: narrowband ultraviolet rays B phototherapy two sessions per week
Study: NCT06767969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophenl 500mg (500mg/50ml) was infused intravenously every 6 hours( a single infusion is completed within 15-30 minutes) from the beginning of endovascular treatment to 48 hours after treatment.
Study: NCT06768814

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sub-acute stabilization
Description: The sub-acute stabilization center (SASC) is for people who have had or are at risk for having an opioid overdose and have an encounter with Seattle Fire Department emergency medical services (EMS) in Seattle, WA. Those transported to the SASC are the intervention participants and two comparison groups will be utilized: eligible Seattle EMS patients who opt not to go to the SASC and King County residents, outside of Seattle, who meet the same eligibility criteria. A comparative interrupted time series analysis is planned to study the main effectiveness outcomes. Seattle Fire EMS will assess, refer, and arrange transport participants to the SASC. The SASC will offer an array of services including post-overdose monitoring, utilization of buprenorphine and methadone for the treatment opioid use disorder and opioid withdrawal, linkage to ongoing care for OUD, and provision of harm reduction services and supplies. The length of stay in the SASC will be limited to less than 24 hours.